Recombinant influenza virus expressing HIV-p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses

Vaccine

Volumn 34, Issue 9, 2016, Pages 1172-1179

  Tan, Hyon Xhi ^a   Gilbertson, Brad P ^a   Jegaskanda, Sinthujan ^a,e   Alcantara, Sheilajen ^a   Amarasena, Thakshila ^a   Stambas, John ^b,c   McAuley, Julie L ^a   Kent, Stephen J ^a,d   De Rose, Robert ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c CSIRO   (Australia)

^d MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CD8 T cell; HIV; Influenza; Mucosal immunity; Prime boost; Vaccine

Indexed keywords

CAPSID PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS 1 P24 CAPSID PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; RECOMBINANT VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; IN VITRO STUDY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MOUSE; MUCOSAL IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT MUCOSA; VAGINA MUCOSA; VIRUS GENE; VIRUS GENOME; VIRUS RECOMBINANT; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LUNG; MUCOSA; SECONDARY IMMUNIZATION; VAGINA;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; FEMALE; GENETIC ENGINEERING; HIV CORE PROTEIN P24; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MICE, INBRED BALB C; MUCOUS MEMBRANE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VAGINA;

EID: 84958093283     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.01.030     Document Type: Article

References (46)

1. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527. 10.1038/nature10003.
2. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998. 10.1084/jem.189.6.991.
3. Price D.A., Goulder P.J.R., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., et al. Positive selection of HIV-cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997, 94:1890-1895.
4. Liu Y., McNevin J., Cao J., Zhao H., Genowati I., Wong K., et al. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 2006, 80:9519-9529. 10.1128/JVI. 00575-06.
5. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
6. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
7. Wilson J.D.K., Ogg G.S., Allen R.L., Davis C., Shaunak S., Downie J., et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 2000, 14:225-233.
8. Reynolds M.R., Rakasz E., Skinner P.J., White C., Abel K., Ma Z-M., et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 2005, 79:9228-9235. 10.1128/JVI.79.14.9228-9235.2005.
9. Sexton A., Rose R.D., Reece J.C., Alcantara S., Loh L., Moffat J.M., et al. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 2009, 83:7619-7628. 10.1128/JVI.00470-09.
10. Reece J.C., Loh L., Alcantara S., Fernandez C.S., Stambas J., Sexton A., et al. Timing of immune escape linked to success or failure of vaccination. PLoS ONE 2010, 5:e12774. 10.1371/journal.pone.0012774.
11. Manicassamy B., Manicassamy S., Belicha-Villanueva A., Pisanelli G., Pulendran B., García-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci USA 2010, 107:11531-11536. 10.1073/pnas.0914994107.
12. Perez J.T., García-Sastre A., Manicassamy B. Insertion of a GFP reporter gene in influenza virus. Curr Protoc Microbiol 2013, 29. G:15G.4:15G.4.1-15G.4.16. 10.1002/9780471729259.mc15g04s29.
13. Szymczak A.L., Workman C.J., Wang Y., Vignali K.M., Dilioglou S., Vanin E.F., et al. Correction of multi-gene deficiency in vivo using a single self-cleaving 2A peptide-based retroviral vector. Nat Biotechnol 2004, 22:589-594. 10.1038/nbt957.
14. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97:6108-6113. 10.1073/pnas.100133697.
15. Cobbin J.C.A., Ong C., Verity E., Gilbertson B.P., Rockman S.P., Brown L.E. Influenza virus PB1 and neuraminidase gene segments can cosegregate during vaccine reassortment driven by interactions in the PB1 coding region. J Virol 2014, 88:8971-8980. 10.1128/JVI. 01022-14.
16. Pejoski D., Zeng W., Rockman S., Brown L.E., Jackson D.C. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol 2010, 88:605-611. 10.1038/icb.2010.15.
17. Ferko B., Stasakova J., Sereinig S., Romanova J., Katinger D., Niebler B., et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol 2001, 75:8899-8908. 10.1128/JVI.75.19. 8899-8908.2001.
18. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789. 10.1182/blood-2005-12-4818.
19. Gherardi M.M., Nájera J.L., Pérez-Jiménez E., Guerra S., García-Sastre A., Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 2003, 77:7048-7057. 10.1128/JVI.77.12. 7048-7057.2003.
20. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., et al. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol 1995, 69:6678-6686.
21. Kittel C., Sereinig S., Ferko B., Stasakova J., Romanova J., Wolkerstorfer A., et al. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 2004, 324:67-73. 10.1016/j.virol.2004.03.035.
22. Heaton N.S., Leyva-Grado V.H., Tan G.S., Eggink D., Hai R., Palese P. In vivo bioluminescent imaging of influenza A virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 2013, 87:8272-8281. 10.1128/JVI.00969-13.
23. Pan W., Dong Z., Li F., Meng W., Feng L., Niu X., et al. Visualizing influenza virus infection in living mice. Nat Commun 2013, 4. 10.1038/ncomms3369.
24. Belshe R.B. Translational research on vaccines: influenza as an example. Clin Pharmacol Ther 2007, 82:745-749. 10.1038/sj.clpt.6100419.
25. Wong S-S., Webby R.J. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26:476-492. 10.1128/CMR. 00097-12.
26. Donnelly M.L.L., Luke G., Mehrotra A., Li X., Hughes L.E., Gani D., et al. Analysis of the aphthovirus 2A/2B polyprotein cleavage mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal skip. J Gen Virol 2001, 82:1013-1025.
27. Kim J.H., Lee S-R., Li L-H., Park H-J., Park J-H., Lee K.Y., et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-in human cell lines, zebrafish and mice. PLoS ONE 2011, 6:e18556. 10.1371/journal.pone.0018556.
28. Novitsky V., Smith U.R., Gilbert P., McLane M.F., Chigwedere P., Williamson C., et al. Human immunodeficiency virus type 1 subtype c molecular phylogeny: consensus sequence for an AIDS vaccine design?. J Virol 2002, 76:5435-5451. 10.1128/JVI.76.11. 5435-5451.2002.
29. Fernandez C.S., Stratov I., Rose R.D., Walsh K., Dale C.J., Smith M.Z., et al. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 2005, 79:5721-5731. 10.1128/JVI.79.9. 5721-5731.2005.
30. Martinez-Picado J., Prado J.G., Fry E.E., Pfafferott K., Leslie A., Chetty S., et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006, 80:3617-3623. 10.1128/JVI.80.7. 3617-3623.2006.
31. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53. 10.1038/nm1520.
32. Masemola A., Mashishi T., Khoury G., Mohube P., Mokgotho P., Vardas E., et al. Hierarchical targeting of subtype c human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 2004, 78:3233-3243. 10.1128/JVI.78.7. 3233-3243.2004.
33. Zuñiga R., Lucchetti A., Galvan P., Sanchez S., Sanchez C., Hernandez A., et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006, 80:3122-3125. 10.1128/JVI.80.6. 3122-3125.2006.
34. Garulli B., Kawaoka Y., Castrucci M.R. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol 2004, 78:1020-1025. 10.1128/JVI.78.2. 1020-1025.2004.
35. Garulli B., Meola M., Stillitano M.G., Kawaoka Y., Castrucci M.R. Efficient vagina-to-lower respiratory tract immune trafficking in a murine model of influenza A virus infection. Virology 2007, 361:274-282. 10.1016/j.virol.2006.12.001.
36. Gallichan W.S., Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996, 184:1879-1890. 10.1084/jem.184.5.1879.
37. Ranasinghe C., Medveczky J.C., Woltring D., Gao K., Thomson S., Coupar B.E.H., et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 2006, 24:5881-5895. 10.1016/j.vaccine.2006.04.023.
38. Ranasinghe C., Eyers F., Stambas J., Boyle D.B., Ramshaw I.A., Ramsay A.J. A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 2011, 29:3008-3020. 10.1016/j.vaccine.2011.01.106.
39. Ranasinghe C., Turner S.J., McArthur C., Sutherland D.B., Kim J-H., Doherty P.C., et al. Mucosal HIV-pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007, 178:2370-2379. 10.4049/jimmunol.178.4.2370.
40. Masopust D., Ha S-J., Vezys V., Ahmed R. Stimulation history dictates memory CD8T cell phenotype: implications for prime-boost vaccination. J Immunol 2006, 177:831-839. 10.4049/jimmunol.177.2.831.
41. Parr M.B., Parr E.L. Interferon-γ up-regulates intercellular adhesion molecule-and vascular cell adhesion molecule-and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2. Immunology 2000, 99:540-545. 10.1046/j.1365-2567.2000.00980.x.
42. Perry L.L., Feilzer K., Portis J.L., Caldwell H.D. Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in chlamydia-infected mice. J Immunol 1998, 160:2905-2914.
43. Lawrence C.W., Braciale T.J. Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 2004, 173:1209-1218. 10.4049/jimmunol.173.2.1209.
44. Shin H., Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012, 491:463-467. 10.1038/nature11522.
45. Mackay L.K., Stock A.T., Ma J.Z., Jones C.M., Kent S.J., Mueller S.N., et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012, 109:7037-7042. 10.1073/pnas.1202288109.
46. Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007, 26:257-270. 10.1016/j.immuni.2007.01.007.